Gerd Glaeske
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gerd Glaeske has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Falk Hoffmann
Department of Health Services Research, Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany
2 shared publications - Kristina Hagenström
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
2 shared publications - Matthias Augustin
Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP) Universitätsklinikum Hamburg‐Eppendorf (UKE) Hamburg Deutschland
2 shared publications - Catharina C. M. Schuiling-Veninga
Department of PharmacoTherapy, -Epidemiology, and -Economics, University of Groningen, 9713 AV Groningen, The Netherlands
1 shared publication - Christian J. Bachmann
Klinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Ulm, Deutschland
1 shared publication - Claudia Garbe
German Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
1 shared publication
Latest Publications
- Open Access
- 1 July 2021
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 13, 593-602
Prevalence and Medications of Atopic Dermatitis in Germany: Claims Data Analysis
Information on the prevalence of atopic dermatitis (AD) varies greatly, and so far, only a few studies describe the healthcare of patients with AD in Germany. The aim of the study is to describe the prevalence and medications of people with AD in Germany. Health insurance data for the year 2019 were examined. Prevalence rates, the severity of disease, comorbidities and pharmaceutical supply were analyzed. Insured persons with AD were identified with at least one outpatient or inpatient International Classification Code of Diseases (L20). In 2019, 4.21% [95% CI 4.21−4.22%] of insured persons had AD (3.6 million). Women were affected slightly more frequently than men (4.74% [95% CI 4.73−4.74%] and 3.64% [95% CI 3.64−3.65%]). Adolescents and children under the age of 15 had the highest prevalence of AD compared to other age groups (9.44% [95% CI 9.42−9.46%]). Majority of the insured persons with AD were affected by a mild to moderate form of the disease. The most common co-morbidity was infections of the skin (RR 5.00 [95% CI 4.97−5.02%]). Some patients were treated by a dermatologist, while others by a general practitioner, 39.10% and 36.74%, respectively. Of the anti-inflammatory drugs, systemic glucocorticosteroids preparations were used most frequently and were most frequently prescribed by the general practitioner. With a total of 42,841 prescriptions (1.53%), methotrexate (third-line treatment option) was prescribed more frequently than ciclosporin with 19,628 prescriptions (0.70%) or azathioprine with 25,696 prescriptions (0.92%). Ciclosporin (first-line treatment option) was prescribed much more frequently by a dermatologist (44.00% versus 14.32% by general practitioner). The biological dupilumab was prescribed 30,801 times (1,10%) and was also primarily prescribed by a dermatologist (66.67%). The present results reveal that a specialist treats approximately one-third of the patients with AD and that there is still a drug undersupply in some cases, especially concerning innovative drugs.
- 1 July 2021
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 13, 593-602
Open AccessPrevalence and Medications of Atopic Dermatitis in Germany: Claims Data Analysis
Information on the prevalence of atopic dermatitis (AD) varies greatly, and so far, only a few studies describe the healthcare of patients with AD in Germany. The aim of the study is to describe the prevalence and medications of people with AD in Germany. Health insurance data for the year 2019 were examined. Prevalence rates, the severity of disease, comorbidities and pharmaceutical supply were analyzed. Insured persons with AD were identified with at least one outpatient or inpatient International Classification Code of Diseases (L20). In 2019, 4.21% [95% CI 4.21−4.22%] of insured persons had AD (3.6 million). Women were affected slightly more frequently than men (4.74% [95% CI 4.73−4.74%] and 3.64% [95% CI 3.64−3.65%]). Adolescents and children under the age of 15 had the highest prevalence of AD compared to other age groups (9.44% [95% CI 9.42−9.46%]). Majority of the insured persons with AD were affected by a mild to moderate form of the disease. The most common co-morbidity was infections of the skin (RR 5.00 [95% CI 4.97−5.02%]). Some patients were treated by a dermatologist, while others by a general practitioner, 39.10% and 36.74%, respectively. Of the anti-inflammatory drugs, systemic glucocorticosteroids preparations were used most frequently and were most frequently prescribed by the general practitioner. With a total of 42,841 prescriptions (1.53%), methotrexate (third-line treatment option) was prescribed more frequently than ciclosporin with 19,628 prescriptions (0.70%) or azathioprine with 25,696 prescriptions (0.92%). Ciclosporin (first-line treatment option) was prescribed much more frequently by a dermatologist (44.00% versus 14.32% by general practitioner). The biological dupilumab was prescribed 30,801 times (1,10%) and was also primarily prescribed by a dermatologist (66.67%). The present results reveal that a specialist treats approximately one-third of the patients with AD and that there is still a drug undersupply in some cases, especially concerning innovative drugs.
- 25 September 2020
- Published by Georg Thieme Verlag KG in Gesundheitsökonomie & Qualitätsmanagement
- Vol. 25 (05) , 249-255
Es ist mehr als nur Medizin erforderlich: Die Corona-Pandemie braucht komplexe Interventionen
Zusammenfassung: In den letzten Monaten hat eine Autorengruppe 4 Thesenpapiere zur Corona-Pandemie publiziert 1, 2, 3, 4, in denen neben Themen wie Epidemiologe und Bürgerrechte auch Aspekte der zielgruppenspezifischen Prävention, insbesondere bei vulnerablen Gruppen, diskutiert werden. Dabei geht es vor allem um Kinder und Frauen, die während des Lockdowns Gewalt und massive Einschränkungen ihrer bisherigen Lebenssituation zu ertragen hatten. Insbesondere Kinder aus Familien oder einer Umgebung mit einem sozial schwachen Status wurden verstärkt benachteiligt, weil ihnen weniger Möglichkeiten zur Aufrechterhaltung ihrer gewohnten Kommunikation als während der Schul- oder Kindergartenzeiten angeboten wurden. Es müssen daher zielgruppenspezifische Präventionsmaßnahmen in Pandemiezeiten verstärkt werden.
- 25 September 2020
- Published by Georg Thieme Verlag KG in Gesundheitsökonomie & Qualitätsmanagement
- Vol. 25 (05) , 249-255
Es ist mehr als nur Medizin erforderlich: Die Corona-Pandemie braucht komplexe Interventionen
Zusammenfassung: In den letzten Monaten hat eine Autorengruppe 4 Thesenpapiere zur Corona-Pandemie publiziert 1, 2, 3, 4, in denen neben Themen wie Epidemiologe und Bürgerrechte auch Aspekte der zielgruppenspezifischen Prävention, insbesondere bei vulnerablen Gruppen, diskutiert werden. Dabei geht es vor allem um Kinder und Frauen, die während des Lockdowns Gewalt und massive Einschränkungen ihrer bisherigen Lebenssituation zu ertragen hatten. Insbesondere Kinder aus Familien oder einer Umgebung mit einem sozial schwachen Status wurden verstärkt benachteiligt, weil ihnen weniger Möglichkeiten zur Aufrechterhaltung ihrer gewohnten Kommunikation als während der Schul- oder Kindergartenzeiten angeboten wurden. Es müssen daher zielgruppenspezifische Präventionsmaßnahmen in Pandemiezeiten verstärkt werden.
- 1 June 2019
- Published by Walter de Gruyter GmbH in Public Health Forum
- Vol. 27 (2) , 110-114
Geschlechts- und genderspezifische Aspekte der Arzneimittelversorgung
Zusammenfassung: In der Arzneimittelversorgung zeigen sich seit vielen Jahren relativ konstant Unterschiede in der geschlechtsspezifischen Verteilung bestimmter Medikamentengruppen. Auffällig ist zum Beispiel die eher leitliniengerechte Verordnung von Arzneimitteln in der Sekundärprävention von Koronarer Herzkrankheit für Männer und die vergleichsweise häufigere Verordnung von Psychopharmaka für Frauen, die oftmals nicht mit den Empfehlungen zur Vermeidung einer inadäquaten Medikation für ältere Menschen übereinstimmt.
- 1 June 2019
- Published by Walter de Gruyter GmbH in Public Health Forum
- Vol. 27 (2) , 110-114
Geschlechts- und genderspezifische Aspekte der Arzneimittelversorgung
Zusammenfassung: In der Arzneimittelversorgung zeigen sich seit vielen Jahren relativ konstant Unterschiede in der geschlechtsspezifischen Verteilung bestimmter Medikamentengruppen. Auffällig ist zum Beispiel die eher leitliniengerechte Verordnung von Arzneimitteln in der Sekundärprävention von Koronarer Herzkrankheit für Männer und die vergleichsweise häufigere Verordnung von Psychopharmaka für Frauen, die oftmals nicht mit den Empfehlungen zur Vermeidung einer inadäquaten Medikation für ältere Menschen übereinstimmt.
- 19 September 2018
- Published by Elsevier in Wound Medicine
- Vol. 23, 58-63
Wound dressings for leg ulcers in Germany: Distribution, regional variations and health care providers
- 19 September 2018
- Published by Elsevier in Wound Medicine
- Vol. 23, 58-63
Wound dressings for leg ulcers in Germany: Distribution, regional variations and health care providers
- 30 August 2018
- Published by Springer Nature
- p. 79-94
Medikamentenabhängigkeit im Alter
- Open Access
- 11 October 2017
- Published by Springer Nature in Child and Adolescent Psychiatry and Mental Health
- Vol. 11 (1) , 55
A multi-national comparison of antipsychotic drug use in children and adolescents, 2005–2012
Over the last decades, an increase in antipsychotic (AP) prescribing and a shift from first-generation antipsychotics (FGA) to second-generation antipsychotics (SGA) among youth have been reported. However, most AP prescriptions for youth are off-label, and there are worrying long-term safety data in youth. The objective of this study was to assess multinational trends in AP use among children and adolescents. A repeated cross-sectional design was applied to cohorts from varied sources from Denmark, Germany, the Netherlands, the United Kingdom (UK) and the United States (US) for calendar years 2005/2006–2012. The annual prevalence of AP use was assessed, stratified by age group, sex and subclass (FGA/SGA). The prevalence of AP use increased from 0.78 to 1.03% in the Netherlands’ data, from 0.26 to 0.48% in the Danish cohort, from 0.23 to 0.32% in the German cohort, and from 0.1 to 0.14% in the UK cohort. In the US cohort, AP use decreased from 0.94 to 0.79%. In the US cohort, nearly all ATP dispensings were for SGA, while among the European cohorts the proportion of SGA dispensings grew to nearly 75% of all AP dispensings. With the exception of the Netherlands, AP use prevalence was highest in 15–19 year-olds. So, from 2005/6 to 2012, AP use prevalence increased in all youth cohorts from European countries and decreased in the US cohort. SGA were favoured in all countries’ cohorts.
- 11 October 2017
- Published by Springer Nature in Child and Adolescent Psychiatry and Mental Health
- Vol. 11 (1) , 55
Open AccessA multi-national comparison of antipsychotic drug use in children and adolescents, 2005–2012
Over the last decades, an increase in antipsychotic (AP) prescribing and a shift from first-generation antipsychotics (FGA) to second-generation antipsychotics (SGA) among youth have been reported. However, most AP prescriptions for youth are off-label, and there are worrying long-term safety data in youth. The objective of this study was to assess multinational trends in AP use among children and adolescents. A repeated cross-sectional design was applied to cohorts from varied sources from Denmark, Germany, the Netherlands, the United Kingdom (UK) and the United States (US) for calendar years 2005/2006–2012. The annual prevalence of AP use was assessed, stratified by age group, sex and subclass (FGA/SGA). The prevalence of AP use increased from 0.78 to 1.03% in the Netherlands’ data, from 0.26 to 0.48% in the Danish cohort, from 0.23 to 0.32% in the German cohort, and from 0.1 to 0.14% in the UK cohort. In the US cohort, AP use decreased from 0.94 to 0.79%. In the US cohort, nearly all ATP dispensings were for SGA, while among the European cohorts the proportion of SGA dispensings grew to nearly 75% of all AP dispensings. With the exception of the Netherlands, AP use prevalence was highest in 15–19 year-olds. So, from 2005/6 to 2012, AP use prevalence increased in all youth cohorts from European countries and decreased in the US cohort. SGA were favoured in all countries’ cohorts.
- 1 September 2017
- Published by Walter de Gruyter GmbH in Public Health Forum
- Vol. 25 (3) , 189-193
Der Arzneimittelmarkt in Deutschland – eine Einführung
Zusammenfassung Der Arzneimittelmarkt in Deutschland ist der viertgrößte der Welt, mit einem Herstellerumsatz von knapp 32 Mrd. Euro. Die Packungsverkäufe bei den rezeptpflichtigen und nicht-rezeptpflichtigen Mitteln sind ähnlich (jeweils rund 750 Mio.), der größte Umsatzanteil (ca. 80%) entfällt auf rezeptpflichtige Mittel wie gentechnologisch oder biologisch hergestellte Mittel, kostengünstiger sind dagegen Biosimilars und Generika. Seit 2011 orientieren sich Preisverhandlungen zu neuen Arzneimitteln durch das AMNOG am Patientennutzen.
- 1 September 2017
- Published by Walter de Gruyter GmbH in Public Health Forum
- Vol. 25 (3) , 189-193
Der Arzneimittelmarkt in Deutschland – eine Einführung
Zusammenfassung Der Arzneimittelmarkt in Deutschland ist der viertgrößte der Welt, mit einem Herstellerumsatz von knapp 32 Mrd. Euro. Die Packungsverkäufe bei den rezeptpflichtigen und nicht-rezeptpflichtigen Mitteln sind ähnlich (jeweils rund 750 Mio.), der größte Umsatzanteil (ca. 80%) entfällt auf rezeptpflichtige Mittel wie gentechnologisch oder biologisch hergestellte Mittel, kostengünstiger sind dagegen Biosimilars und Generika. Seit 2011 orientieren sich Preisverhandlungen zu neuen Arzneimitteln durch das AMNOG am Patientennutzen.
- 28 June 2016
- Published by Springer Nature in Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
- Vol. 59 (8) , 970-978
Trends in der Arzneimittelversorgung von Männern
- 28 June 2016
- Published by Springer Nature in Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
- Vol. 59 (8) , 970-978
Trends in der Arzneimittelversorgung von Männern
- 20 November 2015
- Published by Springer Nature in Der Urologe
- Vol. 54 (12) , 1739-1746
70 plus als Einschlusskriterium – nicht als Ausschluss
- 20 November 2015
- Published by Springer Nature in Der Urologe
- Vol. 54 (12) , 1739-1746
70 plus als Einschlusskriterium – nicht als Ausschluss